Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera
This article was originally published in The Pink Sheet Daily
Company is pursuing priority review, eyes FDA-approval in mid-2012. If Quad is cleared, newly-approved Complera will take back seat.
You may also be interested in...
Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.
It’s Not Just Dosing: Stribild’s Side Effect Profile Could Give It An Edge In HIV Market
Gilead has priced its new 4-in-1 HIV treatment, more commonly referred to as Quad, slightly above the only other integrase inhibitor-based regimen on the market, Merck’s Isentress, but at a 35% premium to its own three-drug combo product, Atripla.
The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.